Heart drug may unlock secrets of blood flow in sepsis

NCT ID NCT07657754

Not yet recruiting Knowledge-focused Sponsor: First Affiliated Hospital of Wannan Medical College Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how esmolol, a drug that slows the heart rate, affects the smallest blood vessels in people with septic shock—a severe infection that can lead to organ failure. Researchers will measure changes in blood flow under the tongue and other key pressures in the circulatory system. The goal is to understand these effects better, not to prove a treatment works. About 20 adults with septic shock and a fast heart rate will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: esmolol
What this could lead to: If successful, this could guide future treatments to improve blood flow in septic shock patients.
What could go wrong: This is a very small pilot study with only 20 patients, so results may not apply broadly. Esmolol can cause low blood pressure or slow heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRITICAL ILLNESS SEPSIS, SEVERE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRITICAL ILLNESS SEPSIS, SEVERE SEPSIS SEPTIC SHOCK

Contacts and locations

Locations

The First Affiliated Hospital of Bengbu Medical University

Bengbu, Anhu, 233000, China
The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College)

Wuhu, Anhui, 241000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.